The firm's financial position is increasingly precarious, evidenced by a current ratio of 0.06 as of 2025Q4 and a reliance on $9.2M of goodwill to support a total asset base of $11.8M.
| Total Current Assets | 2.46M | 502.91K | 2.21M | 5.59M | 8.58M | 509.62K | 341.19K | 613.96K | 102.46K |
| Cash & Short-Term Investments | 1.09M | 334K | 1.92M | 5.46M | 8.42M | 504.75K | 117.15K | 352.39K | 50.71K |
| Cash Only | 1.09M | 334K | 1.92M | 2.58M | 8.42M | 504.75K | 117.15K | 352.39K | 50.71K |
| Short-Term Investments | 0 | 0 | 0 | 2.89M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 211.46K | 3.83K | 49.21K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.37M | 0 | 0 | 14.9K | 0 | 0 | 0 | 250K | 0 |
| Total Non-Current Assets | 9.35M | 9.97M | 295.37K | 358.73K | 75.19K | 142.03K | 202.86K | 7.32K | 18.84K |
| Property, Plant & Equipment | 101.46K | 119.7K | 295.37K | 358.73K | 68.71K | 135.55K | 196.38K | 838 | 18.84K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 9.24M | 9.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 12.12K | 0 | 0 | 6.48K | 6.48K | 6.48K | 6.48K | 0 |
| Total Assets | 11.81M | 10.48M | 2.51M | 5.95M | 8.65M | 651.64K | 544.05K | 621.27K | 121.3K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Asset Growth % | 962.05% | 317.99% | -57.89% | -31.22% | 1227.96% | 19.78% | -12.43% | 412.19% | - |
| Total Current Liabilities | 8.31M | 7.97M | 1.53M | 1.04M | 975.68K | 2.22M | 2.1M | 593.82K | 405.65K |
| Accounts Payable | 1.79M | 1.45M | 596.6K | 283.31K | 129.25K | 828.31K | 516.97K | 30.73K | 79.1K |
| Days Payables Outstanding | 582.75 | - | - | - | 7.9K | 4.97K | 3.43K | 623.16 | 1.54K |
| Short-Term Debt | 0 | 0 | 874.48K | 596K | 685.47K | 849.5K | 686.44K | 400K | 314.38K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 228.39K | 17.54K | 0 |
| Other Current Liabilities | 2M | 2M | 0 | 0 | 0 | 94.03K | 386.31K | 145.54K | 12.16K |
| Current Ratio | 0.30x | 0.06x | 1.44x | 5.37x | 8.79x | 0.23x | 0.16x | 1.03x | 0.25x |
| Quick Ratio | 0.30x | 0.06x | 1.44x | 5.37x | 8.79x | 0.23x | 0.16x | 1.03x | 0.25x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 157.47K | 254.64K | 263.37K | 853.73K | 0 | 62.44K | 129.38K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 135.09K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 659.48K | 154.95K | 238.09K | 304.13K | 0 | 62.44K | 129.38K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 23.42K | 99.69K | 25.28K | 414.51K | 0 | -1 | 0 | 0 | 0 |
| Total Liabilities | 8.46M | 8.22M | 1.8M | 1.9M | 975.68K | 2.28M | 2.23M | 593.82K | 405.65K |
| Total Debt | 214.01K | 232.15K | 1.17M | 1.09M | 748.3K | 978.88K | 874.28K | 400K | 314.38K |
| Net Debt | -875.93K | -101.86K | -746.67K | -1.49M | -7.67M | 474.13K | 757.13K | 47.61K | 263.67K |
| Debt / Equity | 0.06x | 0.10x | 1.65x | 0.27x | 0.10x | - | - | 14.57x | - |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.09x | - | - | - | - | - | - | - | - |
| Interest Coverage | -151.37x | -164.49x | -5.72x | -1.54x | -6.45x | -21.69x | -19.33x | -19.25x | -18.63x |
| Total Equity | 3.35M | 2.25M | 709.15K | 4.06M | 7.68M | -1.63M | -1.69M | 27.46K | -284.35K |
| Equity Growth % | 775.64% | 217.91% | -82.52% | -47.18% | 571.58% | 3.68% | -6256.38% | 109.66% | - |
| Book Value per Share | 6.65 | 13.76 | 0.69 | 2.55 | 7.42 | -1.20 | -1.24 | 0.02 | -0.21 |
| Total Shareholders' Equity | 3.35M | 2.25M | 709.15K | 4.06M | 7.68M | -1.63M | -1.69M | 27.46K | -284.35K |
| Common Stock | 57 | 20 | 41 | 20 | 136 | 93 | 93 | 179 | 450K |
| Retained Earnings | -48.45M | -46.3M | -34.58M | -25.43M | -8.89M | -5.8M | -4.54M | -1.91M | -1.28M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 16.34K | 16.34K | 16.34K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity insolvency risk
As reported in recent financial statements, SHPH's cash reserves plummeted to $334,005 by 2025Q4, resulting in a current ratio of 0.06, which indicates an extreme lack of buffer against near-term operational obligations and suggests the company is currently operating in a state of severe financial distress.
The rapid erosion of liquidity from $4.8M in 2025Q2 to the current level highlights an unsustainable burn rate that leaves little room for clinical trial contingencies. Investors should monitor for immediate dilutive financing events, as the current cash position appears insufficient to support ongoing R&D activities without a significant capital injection.
Based on the 2026Q1 balance sheet, goodwill accounts for $9.2M of the $11.8M total asset base, indicating that the company's valuation is heavily reliant on intangible assets that may be subject to impairment if clinical milestones are not met as anticipated by management.
The high proportion of goodwill relative to total assets suggests that the firm's balance sheet is sensitive to clinical trial outcomes rather than tangible productive capacity. This concentration warrants further investigation into the underlying valuation assumptions, as any failure in the Ropidoxuridine pipeline could necessitate a substantial write-down of these intangible assets.
According to historical balance sheet data, SHPH's equity base has been consistently eroded by accumulated deficits, which reached -$48.5M in 2026Q1, reflecting the ongoing financial strain of funding high-cost clinical development through repeated equity issuance and operational losses.
The persistent negative trend in retained earnings underscores the company's reliance on external capital to offset its lack of commercial revenue. This pattern of equity dilution appears to be the primary mechanism for survival, which may continue to pressure shareholder value until a clear path to commercialization is established.
As indicated by the 2025Q4 data, the company's debt-to-equity ratio of 0.10% appears deceptively low, yet this metric likely masks an inability to access traditional credit markets, forcing the firm into a reliance on dilutive equity financing that fundamentally alters the risk profile for existing shareholders.
While the low debt load might appear favorable in isolation, it likely reflects a lack of collateral or cash flow stability required to secure non-dilutive debt. Consequently, the balance sheet risk is not found in leverage, but in the existential threat posed by the necessity of constant, dilutive capital raises to maintain operations.
Quick answers to the most common questions about buying SHPH stock.
As of 2025, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had total assets of $10.5M including $0.5M in current assets.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) carries total debt of $0.2M, offset by $0.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has total shareholders' equity (book value) of $2.3M ($13.76 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a current ratio of 0.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.